Crocodile farming: a multi-million dollar industry

Crocodiles have a long breeding life, which ranges from 25-30 years. There are 27 species and subspecies of crocodiles throughout the world, 18 of which are in danger of extinction, the rest being threatened with declining population due to overhunting and habitat destruction. Two known crocodile species exist in the Philippines: Crocodylus mindorensis (freshwater crocodile) and C. porosus (saltwater crocodile). Killing adult crocodiles, as is being done now, drastically reduces the potential population. Moreover, toxic wastes from mines, destruction of marshes and riverine habitats, and the conversion of their natural habitats for fishponds additionally threaten their populations. Estimates indicate that there are only about 100 Philippine crocodiles in the wild now. The Crocodile Farming Institute (CFI) was established in Palawan, in 1987, in order to save the crocodiles from extinction in the Philippines. It is now one of the components of the Palawan Wildlife and Conservation Center, and aims to conserve the 2 endangered species in the Philippines and also to develop and introduce a suitable crocodile farming technology that will help uplift the socio-economic well-being of the Filipino people. CFI believes in the potential of commercial utilization of crocodiles as a dollar-generating industry for the Philippines. It is a very profitable business and could be a multi-million dollar industry. A brief outline is given of the economic and marketing potentials of farming crocodiles in the Philippines.

Crocodile industry in Uganda

The foregoing account gives a picture of the exploitation and control of the wild population of Crocodilus niloticus in Uganda from 1920 to the present day. The economic value of the crocodile is shown, and some idea is given of the possibility of maintaining this economic return to Uganda by farming crocodiles in captivity. The Uganda Fisheries Department is actively pursuing the issues which arise from the present status of the wild population, and the need for artificial rearing of crocodiles.

Regulation: A Burden in Biopharmaceutical Industry? The Case of EU-Risk Management Plans

The generation of new medicinal products is both a contributor to global economic growth and a source of valuable benefits to human health. Given their direct responsibility for public health, regulatory authorities monitor closely both the development and exploitation of the underlying technologies and the products derived from them. The manner in which such regulation is implemented can result in regulators constraining or facilitating the generation of new products. This paper will study as an example the impact of EU Risk Management Plans (EU-RMPs), which have been mandatory for the approval of new medicines since 2005, on both the industry and regulatory authorities. In interviews, the responses of those who had experience of the implementation of EU-RMPs were mixed. Although the benefits of a more structured and predictable approach to the evaluation of risk were appreciated, some respondents perceived the regulation as an excessive burden on their organisations. The exploration of factors that influence how EU-RMP regulation affects individual firms provides new insights for both regulators and managers, and demonstrates one aspect of the complexity of the process by which new medicinal products are brought to market.

Regulation: A burden in biopharmaceutical industry? The case of EU-risk management plans

The generation of new medicinal products is both a contributor to global economic growth and a source of valuable benefits to human health. Given their direct responsibility for public health, regulatory authorities monitor closely both the development and exploitation of the underlying technologies and the products derived from them. The manner in which such regulation is implemented can result in regulators constraining or facilitating the generation of new products. This paper will study as an example the impact of EU Risk Management Plans (EU-RMPs), which have been mandatory for the approval of new medicines since 2005, on both the industry and regulatory authorities. In interviews, the responses of those who had experience of the implementation of EU-RMPs were mixed. Although the benefits of a more structured and predictable approach to the evaluation of risk were appreciated, some respondents perceived the regulation as an excessive burden on their organisations. The exploration of factors that influence how EU-RMP regulation affects individual firms provides new insights for both regulators and managers, and demonstrates one aspect of the complexity of the process by which new medicinal products are brought to market. © 2010 IEEE.

Understanding luxury in the premium automotive industry

This paper summarises the findings of investigations to date in understanding what luxury and premiumness mean to the high-end automotive consumer. Existing writings on luxury and premiumness are considered. An exploratory study was carried out in two countries using 309 respondents and 18 prestige cars. A "stream of consciousness" approach was used to capture respondent's views on a selection of vehicles. The codified transcripts were used to identify key differences between the top and bottom rated vehicles, in terms of the nature and quantity of emotional responses elicited. This paper describes some of these key product differences that were self-reported to impact upon a luxury response. Finally, suggestions are made as to the next steps required for this research. © 2007 ACM.